Top

Quality of Life Research

Gepubliceerd in:

01-04-2014

Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT-G)

Auteurs: Adam B. Smith, Kim Cocks, David Parry, Matthew Taylor

Gepubliceerd in: Quality of Life Research | Uitgave 3/2014

Abstract

Purpose

The inclusion of patient-reported outcome (PRO) instruments to record patient health-related quality of life (HRQOL) data has virtually become the norm in oncology randomised controlled trials (RCTs). Despite this fact, recent concerns have focused on the quality of reporting of HRQOL. The primary aim of this study was to evaluate the quality of reporting of HRQOL data from two common instruments in oncology RCTs.

Design

A meta-review was undertaken of systematic reviews reporting HRQOL data collected using PRO instruments in oncology randomised controlled trials (RCTs). English language articles published between 2000 and 2012 were included and evaluated against a methodology checklist.

Results

Four hundred and thirty-five potential articles were identified. Six systematic reviews were included in the analysis. A total of 70,403 patients had completed PROs. The European Organization for Research and Treatment of Cancer QLQ-C30 and Functional Assessment of Cancer Therapy-General questionnaire accounted for 55 % of RCTs. Eighty per cent of RCTs had used psychometrically validated instruments; 70 % reported culturally valid instruments and almost all reported the assessment timing (96 %). Thirty per cent of RCTS reported clinical significance and missing data. In terms of methodological design, only 25 % of RCTs could be categorised as probably robust.

Conclusion

The majority of oncology RCTs has shortcomings in terms of reporting HRQOL data when assessed against regulatory and methodology guidelines. These limitations will need to be addressed if HRQOL data are to be used to successfully support clinical decision-making, treatment options and labelling claims in oncology.

vorige artikel Understanding social forces involved in diabetes outcomes: a systems science approach to quality-of-life research

volgende artikel Assessing the performance of the EQ-VAS in the NHS PROMs programme

Those studies reporting amended or modified versions of these questionnaires were excluded.

This is an underestimation as data on patient numbers were not reported in three trials [14, 17].

Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365–376.PubMedCrossRef

Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. (1993). The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11, 570–579.PubMed

de Haes, J. C., van Knippenberg, F. C., & Neijt, J. P. (1990). Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam symptom checklist. British Journal of Cancer, 62, 1034–1038.PubMedCentralPubMedCrossRef

Spitzer, W., Dobson, A., & Hall, J. (1981). Measuring the quality of life of cancer patients: A concise QL-index for use by physicians. Journal of Chronic Diseases, 34, 585–597.PubMedCrossRef

Brundage, M., Bass, B., Davidson, J., Queenan, J., Bezjak, A., Ringash, J., et al. (2011). Patterns of reporting health-related quality of life outcomes in randomized clinical trials: Implications for clinicians and quality of life researchers. Quality of Life Research, 20, 653–664.PubMedCrossRef

Cocks, K., King, M. T., Velikova, G., Fayers, P. M., & Brown, J. M. (2008). Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. European Journal of Cancer, 44, 1793–1798.PubMedCrossRef

Efficace, F., Osoba, D., Gotay, C., Sprangers, M., Coens, C., & Bottomley, A. (2007). Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Annals of Oncology, 18, 775–781.PubMedCrossRef

Calvert, M., Blazeby, J., Revicki, D., Moher, D., & Brundage, M. (2011). Reporting quality of life in clinical trials: A CONSORT extension. The Lancet, 2011(378), 1684–1685.CrossRef

Efficace, F., Bottomley, A., Osoba, D., Gotay, C., Flechtner, H., D’haese, S., et al. (2003). Beyond the development of health-related quality of life (HRQOL) measures: A checklist for the evaluation of HRQOL evaluation in cancer clinical trials. Journal of Clinical Oncology, 21, 3502–3511.PubMedCrossRef

10.

Blazeby, J. M., Avery, K., Sprangers, M., Pikhart, H., Fayers, P., & Donovan, J. (2006). Health-related quality of life measurement in randomized clinical trials in surgical oncology. Journal of Clinical Oncology, 24, 3178–3186.PubMedCrossRef

11.

Claassens, L., van Meerbeeck, J., Coens, C., Quiten, C., Ghislain, I., Sloan, E. K., et al. (2011). Health-related quality of life in non-small-cell lung cancer: An update of a systematic review on methodologic issues in randomized controlled trials. Journal of Clinical Oncology, 29, 2104–2120.PubMedCentralPubMedCrossRef

12.

Efficace, F., Bottomley, A., & van Andel, G. (2004). Health related quality of life in prostate carcinoma patients: A systematic review of randomized controlled trials. Cancer, 97, 377–388.CrossRef

13.

Efficace, F., Bottomley, A., Vanvoorden, V., & Blazeby, J. M. (2004). Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials. European Journal of Cancer, 40, 187–197.PubMedCrossRef

14.

Efficace, F., Kemmler, G., Vignetti, F., Madelli, F., Molica, S., & Holzner, B. (2008). Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials: A systematic review to evaluate the added value in supporting clinical decision making. European Journal of Cancer, 44, 1497–1506.PubMedCrossRef

15.

Fitzsimmons, D., Gilbert, J., Howse, F., Young, T., Arrarras, J. I., Brédart, A., et al. (2009). A systematic review of the use and validation of health-related quality of life instruments in older cancer patients. European Journal of Cancer, 45, 19–32.PubMedCrossRef

16.

Gujral, S., Avery, K. N., & Blazeby, J. M. (2008). Quality of life after surgery for colorectal cancer: Clinical implications of results from randomised trials. Supportive Care in Cancer, 16, 127–132.PubMedCrossRef

17.

Kvam, A. K., Fayers, P., Hjermstad, M., Gulbrandsen, N., & Wisloff, F. (2009). Health-related quality of life assessment in randomised controlled trials in multiple myeloma: A critical review of methodology and impact on treatment recommendations. European Journal of Haematology, 83, 279–289.PubMedCrossRef

18.

Calvert, M., Blazeby, J., Altman, D. G., Revicki, D. A., Moher, D., Brundage, M. D., et al. (2013). Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO extension. Journal of the American Medical Association, 309(8), 814–822.PubMedCrossRef

19.

Reeve, R. B., Wyrwich, K. W., Wu, A. W., et al. (2013). ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Quality of Life Research. doi:10.1007/s11136-012-0344-y.

Titel: Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT-G)
Auteurs: Adam B. Smith
Kim Cocks
David Parry
Matthew Taylor
Publicatiedatum: 01-04-2014
Uitgeverij: Springer International Publishing
Gepubliceerd in: Quality of Life Research / Uitgave 3/2014
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-013-0534-2

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Design

Results

Conclusion

Log in om toegang te krijgen

Andere artikelen Uitgave 3/2014

Equivalence and measurement properties of an electronic version of the Psoriasis Symptom Inventory

The EORTC QLQ-C15-PAL questionnaire: validation study for Spanish bone metastases patients

Patient-important activity and participation outcomes in clinical trials involving children with chronic conditions

Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial

International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24

Preliminary reliability and validity of Persian version of the Family Dermatology Life Quality Index (FDLQI)